Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...

Ray Lambert looks at the potential of humanized FcRn mice for evaluating the pharmacokinetics of mAbs. Due to their extraordinary specificity and pharmacokinetic (PK) behavior, human ...

Fc receptor based affinity chromatography is a new emerging field of Fc functionality analytics. FcRn affinity columns separate antibody species that differ in their affinity to FcRn using conditions ...

Published in the peer-reviewed journal mAbs, the study presents nipocalimab's high-affinity binding to the neonatal Fc receptor (FcRn) and its capability to significantly reduce IgG levels ...

That means the future of Roivant is tied to the success, or otherwise, of Immunovant’s attempts to break into the FcRn market amid competition from argenx, UCB and, if the FDA signs off on a ...

UCB has the positive result it was hoping for in its phase 3 trial of anti-neonatal FC receptor (FcRn) antibody rozanolixizumab for autoimmune disease generalised myasthenia gravis (gMG), setting ...

Watchers of the percolating myasthenia gravis space are waiting eagerly for data from Dianthus Therapeutics Inc.’s phase II Magic study testing DNTH-103, an active C1s inhibitor, compared to placebo ...

The FDA is reviewing a request for approval of FcRn blocker nipocalimab in generalized myasthenia gravis (gMG). J&J is late to the party, with argenx and UCB already selling rival FcRn blockers ...